FDA Compliant Marketing/Promotions for Pharmaceutical Companies - Best Selling Package Webinar
From Pharmaceuticals
Module 1 : Fraud & Abuse in healthcare sales and marketing – Update on the Law and Tips on Complianc
Learning Objectives:
- About fraud and abuse laws which govern healthcare sales and marketing, e.g. Anti-Kickback Statute, False Claims Act, FDA’s Off-Label Marketing laws, Sunshine Provision, et al.
- How to help keep their sales reps, marketing professionals, and other employees that have contact with healthcare providers in compliance with these laws.
- About companies that have gotten into trouble by promoting their products improperly.
- About resources that help to determine whether behavior is compliant or not, e.g. Federal Safe Harbors [and how to qualify for them], Advisory Opinions, etc.
- Learn the right questions to ask in order to determine if a marketing or sales activity violates the law or not.
- Learn about the consequences to violating the laws.
Areas Covered:
- Introduction/Agenda/Goals.
- Players Involved (FDA, OIG, DOJ, etc).
- Anti-Kickback Statute
- Remuneration – What is it?
- How Detect Problems
- FDA import detention prevention
- Safe Harbors
- Anti-Kickback Analysis
- Examples
- False Claims Act
- Examples
- Off-Label Marketing
- Examples
- Qui Tam Suits
- Examples
- Update on Sunshine Provision and State Laws.
- Questions & Answers.
Module 2 : Appropriate and Lawful Off-Label Dissemination
Areas Covered:
- History: Laws, Regulations, Case law, FDA Guidance.
- What is 'disseminable' today?
- Position of Medical Affairs/Medical Science Liaisons.
- Can sales representatives disseminate information?
- How should it be done? Reviewing your current procedures.
- Training.
- Auditing yourself -- What to look for.
- Dealing with offenders.
Module 3 : Meeting FDA Requirements for Over-the-Counter / OTC Drug Labeling
Areas Covered:
- What are FDA's labeling requirements that differ between NDA vs. OTC Drug Labeling.
- Compliance parameters within FDA's 21 CFR 201 (esp. 201.66) and related sections crucial.
- Goals of FDA's Inspectors in reviewing open market & internet OTC labeling & advertising.
- Examples of acceptable OTC drug labeling.
- Examples of unacceptable OTC drug labeling.
- Enforcements due to illegitimate OTC drug labeling.
Module 4 : Using Social Media in a FDA Compliant Manner
Learning Objectives:
- How Direct-to-consumer-advertising (“DTCA”) guidance impacts the use of social media.
- The ways companies are currently using social media
- FDA advertising and promotion issues related to social media.
- A structure for analysis of responsibility for promotion in social media.
- Recent FDA enforcement situations involving social media.
- Industry proposals on how to govern social media in the future.
Areas Covered:
- How Direct-to-consumer-advertising (“DTCA”) guidance impacts the use of social media.
- The ways companies are currently using social media.
- FDA advertising and promotion issues related to social media.
- A structure for analysis of responsibility for promotion in social media.
- Recent FDA enforcement situations involving social media.
- Industry proposals on how to govern social media in the future.
Who Will Benefit?
The following individuals or disciplines will benefit from these training courses:
- Marketing Management
- Clinical Management
- Attorneys (In-house or Outside Counsel)
- Senior executives of pharmaceutical and device firms
- Regulatory Affairs - Vice Presidents, Directors and Managers
- Sales Vice presidents, Directors and Managers
- Compliance Management
- Sales Management
- QA managers
- Quality system auditors
Instructor Profiles:
(Modules 1,2 & 4)
Mark DuVal, J.D., is President of DuVal & Associates, P.A., a law firm dedicated to counseling companies in the medical device, pharmaceutical, biotech, food, and nutritional supplement industries. His practice includes providing strategic regulatory advice, developing compliance programs, designing and implementing sophisticated marketing programs, counseling on reimbursement matters, conducting sales training and interfacing extensively on behalf of companies with the FDA with relation to product approvals and clearances, clinical trial negotiations, approvals, policy arguments, appeals, etc. Prior to founding the firm, Mark was general counsel for 3M Pharmaceuticals and Drug Delivery Systems working both domestically and internationally. He was on assignment for 3M Health Care Systems, Ltd. In Europe based out of the United Kingdom. He then worked at Medtronic in Corporate Compliance for FDA, Anti-kickback, False Claims Act, HIPAA & HITECH, and other advice related to the FDA-regulated industry.
Mark earned his Juris Doctor from the William Mitchell College of Law where he served as executive editor on the law review, and his Bachelor of Arts in Public Administration from St. Cloud State University. Mark has served on various boards including the Minnesota BioBusiness Alliance, Minnesota Biosciences Council, The Food and Drug Law Institute and has been a former Chairman of the Minnesota State Food, Drug, and Medical Device Section of the Minnesota State Bar Association. He is also on the Board of Advisors of the Masters in Regulatory Affairs Services program at St. Cloud State University. Mark is a frequent national speaker and writer on issues relating to product approvals/clearances; combination products, product advertising and promotion, Anti-kickback and False Claims Act (reimbursement) matters.
(Modules 1,2 & 4)
Mark Gardner, M.B.A., J.D., is an Associate Attorney at DuVal & Associates, P.A., a law firm dedicated to counseling companies in the medical device, pharmaceutical, biotech, food, and nutritional supplement industries. His practice focuses on compliance (federal and state anti-fraud and abuse laws, anti-kickback analysis, HIPAA & HITECH, and development of training and compliance programs) and promotion (appropriate and lawful off-label dissemination procedures, sales contracts, labeling and advertising review, continuing medical education programs (CME), product launch campaigns, pre-approval communications programs, direct-to-consumer (DTC) advertising, and domestic and international web strategy). Prior to joining the firm, Mark worked in the medical device industry for 10 years as a marketer in product management and previously in sales roles. While working at ev3, Celleration, and Medtox Mark focused on commercializing and developing products used for surgical, wound healing, and diagnostic applications.
Mark earned his Juris Doctor from Hamline University School of Law, his Master of Business Administration from the University of St. Thomas, and his Bachelor of Science, Finance and Economics from the University of Wisconsin-La Crosse. Mark is currently serving as Co-Chair for LifeScience Alley's Regulatory Special Interest Group.
(Module 3)
Alfredo J Quattrone, Prior to retiring in Dec 2006, Alfredo Quattrone, PhD, served in the Food and Drug Branch (FDB) of the California Department of Health Services for 19 years as a Staff Toxicologist, assisting with inspections of drug and device manufacturers within CA. During his last 8 years at FDB, Dr. Quattrone directed the State's team for FDA's accredited 3rd party persons medical device review unit, providing direct review support for 36+ device clearances for 510k premarket notification (PMN) submissions to FDA. Dr. Quattrone also coordinated the CA DHS Export Document program for processed foods & dietary supplements, medical devices, and drugs manufactured in California. Since early 2008, Dr. Quattrone has served as a consulting senior scientist affiliate to Auk Technical Services, Inc.
Customer reviews
No reviews were found for FDA Compliant Marketing/Promotions for Pharmaceutical Companies - Best Selling Package Webinar. Be the first to review!